

[View this email in your browser](#)



VALIDATING DIAGNOSTICS TO
COMBAT ANTIMICROBIAL RESISTANCE
BY OPTIMISING ANTIBIOTIC USE

 WWW.VALUE-DX.EU

VALUE-Dx 2021 WAAW Campaign



World Antimicrobial Awareness Week (WAAW) is a campaign that is held annually and was initiated by WHO in 2015. This year, the theme is **'Spread Awareness, Stop Resistance'**. WAAW is celebrated from 18-24 November every year. [Read more.](#)

Point-of-care diagnostic testing (POCT) improves the quality of antibiotic prescription

In August 2021, the VALUE-Dx Consortium has published a [new article](#) in the journal *Health Economics Review* on the use of point-of-care diagnostic testing for improved antibiotic prescription. [Read more.](#)



Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting



interventions in clinical practice, cost-effectiveness analyses can be used. The new [VALUE-Dx publication](#) provides eight recommendations on the reporting and design of CEAs of diagnostics, which can be used in addition to more general guidelines. [Read more.](#)

LAB-Net trained sites in PRUDENCE and ADEQUATE-Paediatric trials

On 17 and 18 September 2021, an online Network Training meeting has officially kicked off PRUDENCE. During this meeting, the sites were trained by the study team on all the aspects of the trial, from patient recruitment to performance of the diagnostic test and completion of the eCRF. Specifically, the [LAB-Net](#) (the laboratory network within [COMBACTE](#) and [Ecraid](#)) team has trained the long term care facilities (LTCF) on sample collection and management for the Microbiology-Biomarker study embedded in PRUDENCE. [Read more.](#)



VALUE-Dx Mid-Term Review meeting



VALUE-Dx's Mid-Term Review meeting was held on 13 October 2021 and brought together VALUE-Dx's Executive Board members, IMI's Scientific Officer and three external reviewers to monitor and discuss project progress. In a full day remote meeting, Executive Board members presented progress and achievements to date as well as planned activities for the coming months and years. [Read more.](#)



Copyright © 2020 VALUE-Dx, All rights reserved.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is:

value_dx@uantwerpen.be

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Organisation · Universiteitsplein · Wilrijk 2160 · Belgium

